



## News Release

### **Suven Life Sciences Presents Positive Preclinical Data for SUVN-502 at Alzheimer's conference, Chicago and Drug Discovery conference, Boston**

**HYDERABAD, INDIA (August 4, 2008)** – Suven presented preclinical data for SUVN-502, its lead 5-HT<sub>6</sub> antagonist drug candidate, at the 2008 Alzheimer's Association International Conference on Alzheimer's Disease (ICAD-2008) in Chicago and Drug Discovery & Development of Innovative Therapeutics (DDT-2008) in Boston. The results demonstrate that SUVN-502 is effective in models of cognition that are considered predictive of efficacy in Alzheimer's disease (AD) and mild cognitive impairment (MCI). In addition, the data suggests the potential for once-daily oral dosing with a favorable safety and toxicology profile.

"We are extremely pleased with the data emerging from our proprietary 5-HT<sub>6</sub> antagonist program. **SUVN-502** produces a robust effect in key models of cognition with a favorable safety and pharmacokinetic profile, providing a strong rationale for clinical development in a cognition indication. We commenced Phase I clinical trials of **SUVN-502** at Basel, Switzerland. The study is expected to be completed by Dec 2008" stated Venkat Jasti, CEO of Suven Life Sciences.

The results were presented in two posters titled "**SUVN-502** - A Potent, Selective, Brain Penetrant and Orally active 5-HT<sub>6</sub> receptor antagonist for the symptomatic treatment of Alzheimer's disease" and "The 5-HT<sub>6</sub> receptor antagonist **SUVN-502** enhances Acetylcholine and Glutamate in rat Ventral Hippocampus and Frontal Cortex - A microdialysis study " The data included the following:

- **SUVN-502** significantly enhanced object recognition in impaired adult rats and aged rats, demonstrating improvements in both acquisition and consolidation memory processes in a model of episodic memory.
- In a model of spatial reference memory and working memory, **SUVN-502** restored cognitive function in aged rats.
- In Microdialysis studies, **SUVN-502** enhances brain acetylcholine and glutamate levels in rat ventral hippocampus and frontal cortex.
- Pharmacokinetic studies of **SUVN-502** both in rats and dogs demonstrated that the compound achieved plasma and brain exposure levels sufficient for once-a-day dosing.
- Blockade of 5-HT<sub>6</sub> receptor by **SUVN-502** after oral administration has an *in vivo* stimulatory effect on cholinergic and glutamatergic neurotransmission in the hippocampus and frontal cortex of rats.

Suven is in discussions for potential licensing partners for this compound. Timing of the licensing would depend on the deal terms and ability to get co-promotion rights in some of the regulated markets. The Company targets launching the molecule in 2012 and aims to be an early launcher in this class. Other molecules in the same category currently under development include GSK's molecule presently in Phase II.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets. The Company has six internally discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease. Parkinson's disease and obesity are in addition to developmental candidates in Alzheimer's disease and Schizophrenia.

#### **Risk Statement:**

**Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;**

